A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Cancer|Soft Tissue Sarcoma|Merkel Cell Carcinoma|Melanoma|Triple Negative Breast Cancer|Non Small Cell Lung Cancer
Interventions: BIOLOGICAL: BT-001|DRUG: Pembrolizumab [Keytruda]
Sponsor: Transgene
Collaborators: BioInvent International AB|Merck Sharp & Dohme LLC